> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Opill as First U.S. Over-the-Counter Daily Birth Control Pill, Ending Prescription Requirement
- URL: https://www.theamericanquorum.com/taq-historical-2023-07-15-healthcare/
- Published: 2023-07-16T03:59:00.000Z
- Updated: 2023-07-16T03:59:00.000Z
- Description: The FDA approved Opill for nonprescription use, making a daily oral contraceptive available without a prescription in the United States for the first time.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-09-01 03:53

The Food and Drug Administration has approved Opill, a progestin-only daily oral contraceptive, for sale without a prescription, making it the first daily birth control pill in the United States cleared for over-the-counter use. The [July 13 decision](https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive?ref=theamericanquorum.com) allows consumers to buy the 0.075-milligram norgestrel tablet at drugstores, grocery and convenience stores and online without first seeing a clinician for a prescription.

The action changes a basic feature of contraceptive access in the United States after decades in which oral birth control remained behind the prescription counter. The FDA said consumers demonstrated in studies that they could understand the Drug Facts label and use the product safely and effectively without assistance from a health professional. The agency emphasized that Opill must be taken at the same time every day and should not be used by people who have or have had breast cancer.

## A unanimous advisory vote preceded the approval

The decision follows a joint meeting in May of the FDA’s Nonprescription Drugs Advisory Committee and Obstetrics, Reproductive and Urologic Drugs Advisory Committee. The agency’s [public meeting record](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-9-10-2023-joint-meeting-nonprescription-drugs-advisory-committee-and-obstetrics-reproductive-and?ref=theamericanquorum.com) includes the FDA and sponsor briefing documents, presentations, questions and transcripts used to evaluate whether consumers could correctly interpret the label and identify circumstances in which they should not use the product.

The panel voted unanimously that the benefits of making Opill available without a prescription outweighed the risks. That recommendation was not binding, but it gave the FDA an independent scientific assessment of the evidence supporting a prescription-to-nonprescription switch.

Perrigo, which acquired HRA Pharma, said in its [approval announcement](https://investor.perrigo.com/2023-07-13-Perrigo-Announces-U-S-FDA-Approval-for-Opill-R-OTC-Daily-Oral-Contraceptive?ref=theamericanquorum.com) that Opill is expected to reach U.S. retailers in early 2024\. The company has not yet announced a retail price, a point that will be central to whether easier legal access translates into practical access for people who currently encounter cost, insurance or appointment barriers.

## The safety case rests on decades of progestin-only use

Opill contains norgestrel and does not contain estrogen. Progestin-only pills have a different risk profile from combined estrogen-progestin contraceptives and have been used for decades. The FDA said the medicine is safe and effective when used as directed, but effectiveness depends heavily on adherence because the tablet must be taken at the same time each day.

Common side effects include irregular bleeding, headaches, dizziness, nausea, increased appetite and abdominal symptoms. The agency also cautioned that some medications can reduce Opill’s effectiveness and that the pill does not protect against sexually transmitted infections. It is not emergency contraception and does not terminate an existing pregnancy.

The approval does not eliminate the role of clinicians in contraceptive care. Patients with questions, abnormal bleeding, suspected pregnancy, medication interactions or relevant cancer history may still need medical evaluation. But the FDA’s decision means a routine office visit is no longer a federal prerequisite for obtaining this particular daily contraceptive.

## Access is the central policy question

Reproductive-health organizations have long argued that prescription requirements create avoidable barriers for people who lack a regular clinician, cannot obtain timely appointments, face transportation constraints or have difficulty paying for a visit. Planned Parenthood called the decision a major access milestone in a [July 13 statement](https://www.plannedparenthood.org/about-us/newsroom/press-releases/planned-parenthood-celebrates-fda-approval-of-first-over-the-counter-birth-control-pill?ref=theamericanquorum.com), while also noting that over-the-counter status alone does not resolve affordability or broader reproductive-health disparities.

The Free the Pill coalition and Ibis Reproductive Health, which have advocated for nonprescription oral contraception for years, described the approval as the result of a long research and policy effort. Their [statement on the decision](https://www.ftpday.freethepill.org/news/fda-approves-first-ever-over-counter-birth-control-pill-united-states?ref=theamericanquorum.com) emphasized the potential benefit for people who face structural barriers to accessing clinicians and prescriptions.

Cost and insurance coverage remain unsettled. Prescription contraceptives are often covered without cost sharing under federal preventive-services requirements, while over-the-counter medicines are not automatically treated the same way. A [contemporaneous report](https://www.washingtonpost.com/health/2023/07/13/birth-control-pill-over-the-counter-fda-approval/?ref=theamericanquorum.com) on the decision noted that advocates are pressing insurers and policymakers to ensure that nonprescription status does not shift costs directly to consumers who previously received prescription contraception through health coverage.

## The change is significant, but narrow

The FDA approval applies to Opill, not to every oral contraceptive. Other formulations and dosages remain prescription products unless manufacturers separately seek and receive permission for nonprescription use. The agency’s decision therefore establishes a precedent rather than an immediate market-wide conversion.

That distinction is important because oral contraceptives differ in hormone composition, dosing and contraindications. The FDA evaluated this specific progestin-only product and the ability of consumers to use its label correctly. Future switches will require their own evidence.

The broader significance is that the agency has accepted the principle that a daily hormonal contraceptive can be safely self-selected and used without a prescription in the U.S. market. That is a substantial change in how contraception is delivered and regulated, and one likely to be measured not only by sales but by whether people who previously encountered prescription barriers gain more reliable control over contraceptive access.